Cilengitide in Treating Patients With Acute Myeloid Leukemia

Inclusion Criteria

• •Diagnosis of acute myeloid leukemia (AML)
• •In first complete remission after at least 1 course of induction chemotherapy AND 1-2 courses of consolidation chemotherapy for newly diagnosed AML, as defined by the following:
• •* No evidence of disease in bone marrow
• •* Recovery of peripheral blood counts
• •* Platelet count \> 100,000/mm\^3
• •* Absolute neutrophil count \> 1,500/mm\^3
• •Must be able to start study medication within 60 days from the start of the last consolidation therapy
• •Must not have a suitable donor, refused, or ineligible for hematopoietic stem call transplantation
• •None of the following AML subtypes or chromosomal translocations:
• •* Acute promyelocytic leukemia
• •* t(8;21)
• •* t(16;16)
• •* inv(16)
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •See Disease Characteristics
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •ALT ≤ 2.5 times ULN
• •Creatinine ≤ 1.5 times ULN
• •Creatinine clearance \> 60mL/min
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •No other uncontrolled illness
• •No prior investigational agents specifically designated as an antiangiogenic agent
• •No concurrent prophylactic hematopoietic colony-stimulating factors
• •See Disease Characteristics
• •Recovered from prior consolidation chemotherapy
• •No other concurrent anticancer therapies
• •No other concurrent investigational cytotoxic agents